© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Johnson & Johnson (JNJ) stock declined over -1.69%, trading at $234.63 on NYSE, down from the previous close of $238.67. The stock opened at $237.42, fluctuating between $234.51 and $238.14 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 235.01 | 242.19 | 233.25 | 240.10 | 10.12M |
| Apr 13, 2026 | 237.71 | 238.39 | 235.18 | 237.96 | 7.27M |
| Apr 10, 2026 | 242.00 | 242.26 | 237.91 | 238.46 | 7.33M |
| Apr 09, 2026 | 241.30 | 244.20 | 240.54 | 241.31 | 6.09M |
| Apr 08, 2026 | 236.64 | 241.33 | 233.90 | 241.30 | 8.76M |
| Apr 07, 2026 | 240.78 | 240.78 | 236.01 | 238.41 | 6.23M |
| Apr 06, 2026 | 242.65 | 243.52 | 240.50 | 240.97 | 4.44M |
| Apr 02, 2026 | 245.11 | 247.21 | 241.87 | 243.04 | 6.61M |
| Apr 01, 2026 | 245.60 | 247.20 | 243.74 | 244.12 | 6.31M |
| Mar 31, 2026 | 243.01 | 245.33 | 242.65 | 244.44 | 7.55M |
| Mar 30, 2026 | 243.49 | 244.21 | 240.51 | 242.49 | 7.22M |
| Mar 27, 2026 | 241.19 | 242.68 | 239.13 | 240.45 | 7.55M |
| Mar 25, 2026 | 236.80 | 241.46 | 235.73 | 239.93 | 6.45M |
| Mar 24, 2026 | 234.14 | 236.00 | 232.24 | 235.27 | 8.82M |
| Mar 23, 2026 | 237.40 | 238.31 | 234.25 | 235.42 | 7.3M |
| Mar 20, 2026 | 236.83 | 238.29 | 234.50 | 235.37 | 17.07M |
| Mar 19, 2026 | 238.34 | 239.26 | 236.31 | 237.60 | 7.48M |
| Mar 18, 2026 | 237.87 | 239.11 | 235.42 | 237.28 | 6.67M |
| Mar 17, 2026 | 243.58 | 244.14 | 237.22 | 238.11 | 7.1M |
| Mar 16, 2026 | 243.92 | 245.06 | 241.67 | 243.19 | 7.56M |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
| Employees | 138100 |
| Beta | 0.33 |
| Sales or Revenue | $85.15B |
| 5Y Sales Change% | 0.097% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |